Search Within

Shanu Modi

  1. "Radiology, Department of"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (24)
  3. Review (1)
Groups
  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Radiology, Department of (55)
  4. Solid Tumor Oncology Division (55)
  5. GSK Faculty (42)
  6. Survivorship Research (42)

More Groups

People
  1. Clifford Hudis (36)
  2. Larry Norton (22)
  3. Sujata Patil (20)
  4. Komal Jhaveri (17)
  5. Sarat Chandarlapaty (15)
  6. Diana Lake (14)

More People

Years
  1. 2024 (2)
  2. 2022 (3)
  3. 2021 (3)
  4. 2020 (3)
  5. 2019 (8)
  6. 2018 (1)

More Years

Publications
  1. Cancer Research (13)
  2. Journal of Clinical Oncology (11)
  3. Clinical Cancer Research (4)
  4. Annals of Oncology (3)
  5. Clinical Breast Cancer (3)
  6. Breast Cancer Research and Treatment (2)

More Publications

Publishers
  1. American Association for Cancer Research (18)
  2. American Society of Clinical Oncology (12)
  3. Elsevier Inc. (6)
  4. Oxford University Press (4)
  5. Nature Publishing Group (3)
  6. Springer (2)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Cadoo, K.; Chandarlapaty, S.; Teplinsky, E.; Speyer, J.; D'Andrea, G.; Patil, S.; Haque, S.; Friedman, K.; Heese, S.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions
    Journal Article

    Jhaveri, K.; Ochiana, S. O.; Dunphy, M. P. S.; Gerecitano, J. F.; Corben, A. D.; Peter, R. I.; Janjigian, Y. Y.; Gomes DaGama, E. M.; Koren, J. 3rd; Modi, S.; more...
    Expert Opinion on Investigational Drugs (2014)

    Fulltext@MSK | Save
  • Using (124)I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Gajria, D.; Taldone, T.; Alpaugh, M.; DaGama, E. G.; Uddin, M.; Chiosis, G.; Lewis, J. S.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save